Published on 09/01/2026

Strategies to Manage Pre- and Post-Market Approvals for Companion Diagnostics

Understanding the Regulatory Lifecycle of a Companion Diagnostic

Companion diagnostics (CDx) are essential tools for personalized medicine. From initial clinical validation to ongoing performance monitoring, CDx developers must address both pre-market and post-market regulatory requirements. Each stage comes with specific documentation, compliance obligations, and regulatory interactions, especially across agencies like the FDA, EMA, and PMDA.

This tutorial explains the regulatory expectations for CDx at both pre-market and post-market stages, comparing regional requirements and outlining best practices for global compliance.

Pre-Market Approvals: Foundation for Market Entry

Pre-market approval refers to the regulatory process by which a CDx obtains authorization to enter the market. This typically involves a thorough review of safety, analytical performance, and clinical validation data.

• FDA: Companion diagnostics require Premarket Approval (PMA). If used in clinical trials, an Investigational Device Exemption (IDE) may be needed.
• EU: Under IVDR, CDx must undergo conformity assessment involving both a Notified Body and a consultation with EMA (Article 48).
• Japan: PMDA reviews the CDx dossier, and MHLW grants marketing authorization. Clinical bridging studies may be needed for foreign data.

Sample data expectations for analytical validation include:

Essential Components of a Pre-Market Submission

A typical CDx submission includes:

• Analytical performance report (LOD, LOQ, precision, specificity)
• Clinical trial evidence showing correlation with therapeutic response
• Labeling and Instructions for Use (IFU) with intended use clearly stated
• Quality Management System (QMS) compliance documentation (e.g., ISO 13485)
• Stability testing data (e.g., accelerated aging, real-time stability)

Further guidance can be found at FDA’s Companion Diagnostic Guidance.

Transitioning from Pre- to Post-Market: What Changes?

Once a CDx is approved and commercialized, regulatory focus shifts to post-market activities such as performance monitoring, complaint handling, labeling updates, and change control.

Key transitions include:

• Ongoing performance evaluation (e.g., batch release testing, trending)
• Post-Market Surveillance (PMS) and Vigilance reporting
• Change control for software updates, manufacturing shifts, or design changes
• Periodic Safety Update Reports (PSUR) under EU IVDR

Explore lifecycle QMS expectations at PharmaGMP.in.

Post-Market Vigilance Obligations Across Agencies

Each region has distinct requirements for post-market oversight:

• FDA: Medical Device Reporting (MDR) is required for serious adverse events. Field safety corrective actions must be documented.
• EMA/IVDR: Notified Bodies audit PMS reports. Significant incidents must be reported within 15 days.
• Japan (PMDA): Re-evaluation is mandated every 5 years. Adverse event trends must be reported to MHLW.

Example: If a diagnostic batch shows loss of sensitivity (LOD drift from 0.1 ng/mL to 0.3 ng/mL), it may trigger a product recall or re-validation requirement.

Managing Post-Market Changes: Design and Manufacturing Updates

Common post-market changes include:

• Change in raw materials (e.g., antibody clone)
• Device software upgrades impacting result interpretation
• Labeling updates (e.g., indication expansion)
• Site transfer for manufacturing

Regulatory approval may be required depending on the risk level of the change:

Post-Market Clinical Follow-Up (PMCF)

PMCF involves collecting clinical data on the performance of a CDx in the real-world setting. It helps identify rare issues and performance drifts not observed during trials.

• Under IVDR: PMCF is mandatory for Class C CDx
• Data Collection: Includes retrospective studies, registry data, and real-world evidence
• Documentation: Must be included in the Post-Market Surveillance Plan (PMSP)

Example: A CDx detecting BRAF mutations in melanoma patients might need PMCF to assess performance in diverse ethnic populations.

Case Study: Post-Market Labeling Update for a CDx

A US-based diagnostic company expanded the use of its EGFR CDx from NSCLC to colorectal cancer based on post-market data. The process involved:

• Real-world data submission from 3,000 patients
• Supplemental PMA application to FDA
• Revised IFU and labeling
• Training updates for laboratory users

Outcome: Approval granted in 6 months, resulting in increased market adoption and improved patient outcomes.

Risk Management in the Post-Market Phase

Risk-based monitoring and CAPA (Corrective and Preventive Action) processes are essential. Risk management includes:

• Periodic risk re-evaluation based on PMS and complaint trends
• Root cause analysis for adverse events
• Implementation of corrective actions and effectiveness checks
• Updated risk management file (RMF) per ISO 14971

Audit Readiness and Inspection Preparation

Regulators may audit post-market CDx activities, especially after field actions. Be ready with:

• PMS reports and trending analysis
• Field Safety Notices (FSNs) and recall logs
• CAPA reports and effectiveness checks
• Evidence of training and QMS updates

Regular internal audits aligned with ICH QMS Guidelines are recommended.

Conclusion

Managing the regulatory lifecycle of a companion diagnostic requires equal focus on pre-market and post-market phases. While pre-market approval establishes a product’s safety and efficacy, post-market surveillance ensures sustained performance in the real world. Regulatory teams must maintain proactive vigilance, robust documentation, and seamless change control processes to remain compliant and responsive to patient needs and regulatory scrutiny worldwide.